Swk Holdings CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
SWK Holdings Corporation reported a net loss of $2.5 million for the fiscal year ended December 31, 2025, driven by a strategic divestiture of its Pharmaceutical Development segment and increased tax expense.
SWK Holdings Corporation's 2024 10-K filing reveals a strategic shift towards its Finance Receivables segment, alongside mixed financial performance and key management changes.
SWK Holdings Corporation's 2023 10-K filing reveals a year of strategic shifts, including a significant goodwill impairment, alongside growth in finance receivables and ongoing pharmaceutical development efforts.